GRTX — Galera Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $10.12m
- $142.91m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 50.7 | 70.6 | 73.4 | 51.2 | 49.3 |
Operating Profit | -50.7 | -70.6 | -73.4 | -51.2 | -49.3 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -51.9 | -74.2 | -80.5 | -62.3 | -59.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -51.9 | -74.2 | -80.5 | -62.2 | -59.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -51.9 | -74.2 | -80.5 | -62.2 | -59.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -59.1 | -74.2 | -80.5 | -62.2 | -59.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.38 | -2.98 | -3.12 | -2.3 | -1.27 |